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Abstract 23 
Bacterial pathogens such as Staphylococcus aureus and Staphylococcus epidermidis can 24 
survive in different types of cells including professional phagocytes, causing intracellular 25 
infections. Antibiotic treatment of intracellular infections is often unsuccessful due to the low 26 
efficacy of most antibiotics inside cells. Therefore, novel techniques which can improve 27 
intracellular activity of antibiotics are urgently needed. We aimed to use photochemical 28 
internalization (PCI) to enhance cytosolic release of antibiotics from endocytic vesicles after 29 
internalization. Our results show that PCI indeed caused cytosolic release of gentamicin and 30 
significantly increased its efficacy against S. epidermidis in vitro in mouse macrophages. Upon 31 
illumination for 15 min, the killing of intracellular S. epidermidis in RAW 264.7 cells by 10 or 32 
30 g/ml gentamicin was increased to 1 or 3 CFU log, respectively, owing to the use of PCI, 33 
whereas no killing by gentamicin only without PCI was observed. Moreover, survival of S. 34 
aureus-infected zebrafish embryos was significantly improved by treatment with PCI-35 
gentamicin. PCI improved the therapeutic efficacy of gentamicin at a dose of 0.1 ng per embryo 36 
to a level similar to that of a dose of 0.4 ng per embryo, indicating that PCI can lower the 37 
antibiotic dose required for treating (intracellular) staphylococcal infection. Thus, the present 38 
study shows that PCI is a promising novel approach to enhance the intracellular efficacy of 39 
antibiotics via cytosolic release, allowing them to reach intracellular bacteria. This will expand 40 
their therapeutic window and will increase the numbers of antibiotics which can be used for 41 
treatment of intracellular infections.  42 
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Introduction 48 
As an opportunistic intracellular pathogen, Staphylococcus aureus can survive in several types 49 
of cells including professional phagocytes such as macrophages and neutrophils, resulting in 50 
high frequencies of occurrence of intracellular infections, possibly leading to life-threatening 51 
infectious diseases such as biomaterial associated infection, endocarditis and sepsis [1-6]. The 52 
closely related commensal Staphylococcus epidermidis also can colonize healthy tissues and 53 
persist intracellularly in macrophages after implantation of biomaterials [7-10]. Like 54 
staphylococci, important bacterial pathogens such as Mycobacterium tuberculosis, Listeria 55 
monocytogenes, and Salmonella typhi can survive intracellularly and cause tuberculosis, 56 
meningitis and typhoid fever, respectively [11, 12]. 57 
Intracellular infections are very difficult to treat since most antibiotics have limited activity 58 
against intracellular bacteria [11-14], because of low penetration of eukaryotic cells [13], low 59 
intracellular retention [13], or high frequencies of resistance development [15]. Resistance may 60 
develop since the low, permissive intracellular concentrations of antibiotics provide a selective 61 
advantage for bacteria with reduced susceptibility [16]. Moreover, some pathogens such as S. 62 
aureus may undergo structural changes inside the host cells, resulting in reduction of sensitivity 63 
to antibiotics [2]. Thus, techniques for improving intracellular activity of antibiotics are 64 
urgently required. Cellular internalization of antibiotics and other biomolecules can be 65 
enhanced by using liposomes, polymeric micro-/nanoparticles and (nano-)biomimetic as 66 
carriers [11, 12, 14, 17], conjugation to specific antibodies, provoking receptor-mediated uptake 67 
[18], or conjugation to cell penetrating peptides [19, 20]. However, development of delivery 68 
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systems or conjugation systems is complex and/or often targeted to single types of antibiotics, 69 
and modifications of the molecular structures of antibiotics may reduce their activity [21]. 70 
Moreover, most of these approaches will hardly mediate efficient release of the cargos from 71 
endocytic vesicles into the cytosol [22, 23]. Endosomal entrapment of many therapeutics is 72 
known to hinder them from reaching their intracellular site of action and will eventually result 73 
in degradation of the entrapped drugs in lysosomes [22, 23]. 74 
To solve this problem, photochemical internalization (PCI) would be a promising method to 75 
improve cytosolic release of therapeutics and as a result enhance their intracellular efficacy. 76 
PCI has recently been developed to improve intracellular efficacy of drugs for tumor treatment 77 
using amphiphilic photosensitizers e.g. tetraphenyl phorphyrin disulphonate (TPPS2a) and 78 
tetraphenyl chlorin disulphonate (TPCS2a) (Figure S1, Supplementary data) [24, 25]. In PCI, 79 
photosensitizers localize to the membranes of endocytic vesicles in which drugs may be 80 
sequestered within cells. Upon illumination, these photosensitizer-bound membranes are 81 
disrupted, causing cytosolic release of the drugs from the vesicles allowing them to reach their 82 
intracellular targets [24, 25].  83 
In the present study, we therefore assessed whether PCI combined with antibiotics can combat 84 
intracellular bacterial infection by enhancing cytosolic release of the antibiotics. Different from 85 
the application of PCI for tumor treatment which aims for an effect on the entire target cancer 86 
cells, we used PCI to deliver antibiotics intracellularly to target another organism, i.e. the 87 
intracellular bacteria. This novel concept is depicted in Scheme 1. Gentamicin was selected as 88 
the antibiotic since it has low intracellular activity due to its inability of endosomal escape [26, 89 
27]. The efficacy of gentamicin against intracellular staphylococci with and without PCI was 90 
evaluated in vitro in RAW 264.7 mouse macrophages and in vivo using a zebrafish embryo 91 
staphylococcal infection model [4, 28]. To the best of our knowledge, our study is the first to 92 
demonstrate this potential of PCI in an entirely new application field, i.e. to improve 93 
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intracellular efficacy of antibiotics, and to show proof of concept of this novel approach to treat 94 
intracellular infections.  95 
 96 
97 
Scheme 1. Proposed mechanism of photochemical internalization (PCI) of antibiotics 98 
combatting intracellular bacteria. a) Cellular uptake of antibiotics and bacteria; amphiphilic 99 
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photosensitizers (PS) are administered together with antibiotics and dock into the plasma 100 
membrane prior to the formation of endosomes (insertion of TPCS2a in magnification); b) 101 
Entrapment of antibiotics and bacteria in endosomes/phagosomes; c) PCI–induced cytosolic 102 
release of antibiotics by disrupting the membranes of endosomes upon illumination and 103 
concomitant dissociation of PS; dashed arrow indicates re-location [29] of liberated PS to the 104 
membranes of phagosomes containing bacteria during illumination, causing PCI-induced 105 
cytosolic release of bacteria. d) Contact of antibiotics with bacteria within the cytosol allowing 106 
antimicrobial action. Of note, the sizes of the symbol of antibiotics, bacteria and 107 
photosensitizers are schematic, not proportional to their actual molecular/cell sizes. (in color) 108 
 109 
Materials and methods  110 
Bacterial strains and inoculum preparation 111 
S. epidermidis strain O-47 [7] was used for in vitro studies with RAW 264.7 mouse 112 
macrophages (indicated as RAW cells in the manuscript, #TIB-71 ATCC, U.S) [30]. The 113 
minimal inhibitory concentration (MIC) and minimal bactericidal concentration (MBC) [27] of 114 
gentamicin (Centrafarm B.V, The Netherlands) for S. epidermidis strain O-47 in RPMI medium 115 
(Gibco, ThermoFisher Scientific) were 0.04 and 0.33 µg/ml, respectively. S. aureus strain 116 
ATCC#49230 was used for zebrafish embryo infection. S. aureus strain RN4220 expressing 117 
mCherry fluorescent protein (designated as S. aureus-mCherry in the manuscript) was 118 
constructed as described [7, 31] and used for in vivo visualization of cell-bacteria interaction in 119 
zebrafish embryos. Bacterial inocula were prepared as described [7, 31].  120 
 121 
Culturing condition of RAW 264. 7 cells 122 
 7 
RAW cells were seeded in 96-well plates (Greiner bio-one) at a concentration of 1 x 105 123 
cells/well and incubated overnight in RPMI medium supplemented with 5 % fetal calf serum 124 
(RPMI) (Gibco, ThermoFisher Scientific) at 37 °C in a humidified atmosphere containing 5 % 125 
CO2.   126 
 127 
Cytotoxicity for RAW cells 128 
Cultured RAW cells were incubated overnight in 200 µl of RPMI containing gentamicin (15.6 129 
to 1000 μg/ml), or incubated for 2 hours in RPMI containing the photosensitizer TPPS2a (0.1 to 130 
0.4 µg/ml) (PCI Biotech AS, Norway). The TPPS2a-treated cells were incubated for another 2 131 
hours in fresh RPMI in order to remove excess TPPS2a from cytoplasma membranes. RAW 132 
cells incubated in RPMI alone served as controls. Cells were protected from light except during 133 
illumination for 15 minutes using the LumiSource device (a broad-band blue light source, λmax 134 
≈ 420 nm; PCI Biotech AS). After illumination, cells were incubated in fresh RPMI for 24 135 
hours.  The effect of gentamicin and of TPPS2a on the metabolic activity of RAW cells was 136 
tested using MTT assay at 24 hours after incubation or using WST-1 assay directly and at 24 137 
hours after illumination, respectively, according to the manufacturer’s instruction (Sigma-138 
Aldrich). In order to test the effect of TPPS2a alone or combined with S. epidermidis on the 139 
viability of RAW cells, cells were either allowed to phagocytose bacteria for 45 minutes (assay 140 
described below) or incubated in bacteria-free medium. After phagocytosis, the cells were 141 
incubated in 200 µl of RPMI containing 0.25 µg/ml TPPS2a for 2 hours, and then incubated in 142 
fresh RPMI for another 2 hours to remove excess cell membrane-bound TPPS2a and 143 
subsequently illuminated for 0, 5, 10 or 15 minutes. Cells only illuminated served as controls. 144 
The influx of propidium iodide was measured to quantify the loss of cell viability directly or at 145 
24 hours after illumination. 146 
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 147 
In vitro phagocytosis assay 148 
After culturing in Tryptic Soy Broth (TSB) medium, S. epidermidis bacteria were pelleted by 149 
centrifugation (208,000 x g, 2 minutes), re-suspended in 1.5 ml of PBS mixed with 0.5 ml of 150 
human serum (H1 serum, Bio Whittaker, The Netherlands) and incubated for 20 minutes for 151 
opsonization. The inoculum was adjusted to 1 x 108 CFU/ml with RPMI. The cells were seeded 152 
as described above and medium of cells was replaced by 40 µl of the bacterial inoculum 153 
(bacteria to cell ratio of 40:1) and phagocytosis was allowed to proceed for 45 minutes. RAW 154 
cells were then gently washed four times with 60 µl, and with a final wash with 200 µl of PBS 155 
to prevent carry-over of planktonic S. epidermidis, which was always less than 0.5 % of the 156 
numbers of retrieved intracellular bacteria after these washing steps. Cells were lysed with 100 157 
µl of 1 % saponine. After lysis, the PBS containing lysed cells and bacteria was transferred into 158 
a vial and centrifuged (208,000 x g, 2 minutes). The pelleted bacteria were washed and re-159 
suspended in fresh PBS before quantitative culture of serial 10-fold dilutions[31]. Intracellular 160 
surviving S. epidermidis in RAW cells were expressed as numbers of CFU per well. The 161 
phagocytosis assay is schematically depicted in Figure S2 (Supplementary data). 162 
 163 
Bactericidal activity assay  164 
To test whether photosensitizer TPPS2a has bactericidal activity against S. epidermidis, we 165 
performed a 99.9% lethal concentration assay. After pre-culture in TSB medium, an S. 166 
epidermidis inoculum was prepared of 1 x 106 CFU/ml with refresh TSB medium.  One hundred 167 
l of the inoculum was added to 100 l of TSB medium containing different concentrations of 168 
TPPS2a (final concentrations of 0.005 to 0.5 g/ml) in a 96 wells plate. After overnight 169 
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incubation with TPPS2a, the bacteria were illuminated for 6 minutes using the LumiSource 170 
device, and quantitatively cultured immediately and at 3 and 24 hours after illumination, as 171 
described earlier. Bacteria incubated in TSB medium without TPPS2a served as controls. The 172 
concentration of TPPS2a eliminating 99.9% of the numbers of CFU relative to the inoculum 173 
was defined as the 99.9% lethal concentration (LC99.9)。  174 
 175 
Intracellular antimicrobial activity assay 176 
RAW cells were allowed to phagocytose S. epidermidis.  This bacterial species was chosen for 177 
these experiments since the bacteria survive inside the macrophage in vitro without killing them 178 
[32]. Cells were then washed to remove extracellular bacteria as described earlier, and treated 179 
for 2 hours with gentamicin (1, 10 or 30 µg/ml) with or without TPPS2a (0.25 µg/ml) (Figure 180 
S2, Supplementary data). Cells incubated in RPMI or in RPMI containing TPPS2a served as 181 
controls. The medium was then changed for fresh RPMI containing gentamicin in the identical 182 
concentrations but without TPPS2a, and cells were incubated for 2 hours to remove excess cell 183 
membrane-bound TPPS2a. Medium was then replaced by RPMI containing 1 µg/ml gentamicin 184 
in order to prevent growth of extracellular bacteria in the subsequent steps, and cells were 185 
illuminated for 10 or 15 minutes. Non-illuminated cells served as controls. After illumination 186 
cells were incubated overnight, lysed, and intracellular surviving bacteria were quantitatively 187 
cultured as described earlier.   188 
 189 
Preparation of fluorescently labeled gentamicin  190 
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Gentamicin (Sigma-Aldrich) was labelled with Alexa Fluor 405 succinimidyl ester (Life 191 
Technologies) (ratio of 1:1), purified by C-18 reversed phase chromatography, aliquoted, 192 
lyophilized and stored in the dark at -20°C. 193 
 194 
Confocal fluorescence microscopy  195 
After culturing, RAW cells were seeded in a culture dish at 3x105 cells/dish (MatTek Glass 196 
Bottom Culture Dish, U.S) and incubated overnight in 1 ml of RPMI containing 10 μg/ml 197 
fluorescently labeled gentamicin alone or combined with 1 μg/ml TPCS2a (PCI Biotech AS). 198 
The cells were then incubated in fresh RPMI for 4 hours to remove excess cell membrane-199 
bound TPCS2a, illuminated for 2 minutes and covered with Prolong® Gold antifade reagent (Life 200 
Technologies) for confocal microscopy (Leica).  201 
 202 
Zebrafish husbandry and maintenance 203 
The zebrafish embryo experiments were performed according to the EU Animal Protection 204 
Directive 2010/63/EU. Adult wild type (WT) or transgenic (Tg) zebrafish and embryos were 205 
maintained as described [33] and handled in compliance with animal welfare regulations, as 206 
approved by the local animal welfare committee (DEC).  207 
 208 
Injection into zebrafish embryos 209 
Injections of antibiotic solution (alone or with photosensitizers) or bacterial inoculum into the 210 
blood circulation of zebrafish embryos via either the blood island or the duct of Cuvier was 211 
performed as described [34]. An injection volume of 1 nl was used for all injections performed 212 
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in the present study. The needles were pulled from a glass capillary (Harvard apparatus) and 213 
the tip was broken at an outer diameter of approximately 15 µm using a microscope with a scale 214 
bar (Leica M20) [34]. Pressure and injection time of the FemtoJet microinjector (Eppendorf) 215 
were subsequently adjusted to deliver liquid droplets with a diameter of 125 µm, corresponding 216 
to a calculated volume of 1 nl.   217 
 218 
Dose finding of S. aureus for zebrafish embryo infection 219 
Using graded inocula of S. aureus (ATCC#49230 strain; 6000, 3000, 500 and 100 CFU per 220 
embryos), we assessed the lethal challenge dose for zebrafish embryos. Embryos were injected 221 
at 30 hours post fertilization, and individually maintained in 200 μl of E3 medium as described 222 
[33]. Medium was refreshed daily. The injected doses were checked by quantitative culture of 223 
5-6 embryos per group, crushed using a MagNA lyser (Roche). Survival was monitored daily 224 
until 4 days post injection.  225 
 226 
Visualization of co-localization of phagocytes and bacteria in zebrafish embryos  227 
At 30 hours post fertilization, inocula of S. aureus-mCherry were injected into zebrafish 228 
embryos of the Tg line (mpeg1: Gal4/UAS: Kaede) featuring macrophages expressing Kaede 229 
green fluorescent protein [35]. The injected doses were checked as described above. At 32 hours 230 
post fertilization, so 2 hours post injection, images were recorded under bright field as well as 231 
with the FITC and mCherry filters, using a fluorescence microscope (LM 80, Leica).  232 
 233 
Toxicity for zebrafish embryos 234 
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Gentamicin (0.16 to 16 mg/ml) or TPCS2a (0.25 to 25 µg/ml) solutions (both in PBS) or 235 
mixtures were injected into WT zebrafish embryos at 32 hours post fertilization. Control 236 
embryos received PBS injections. The embryos were group-wise maintained in petri-dishes, 237 
and protected from light except during illumination for 10 minutes with the LumiSource to 238 
activate the TPCS2a photosensitizer, at 34 hours post fertilization. Survival of embryos was 239 
monitored daily until 6 dpi based on the observation of movement and heartbeat of the embryos. 240 
 241 
Treatment of S. aureus-infected zebrafish embryos  242 
Wild type zebrafish embryos were injected with 3000 CFU of S aureus ATCC#49230 at 30 hpf, 243 
and randomly divided into groups for different treatments. At 32 hours post fertilization 1 nl of 244 
PBS solution containing gentamicin alone (0.05, 0.1 or 0.4 μg/ml) or combined with 0.25 μg/ml 245 
TPCS2a was injected. Control embryos received PBS injections. The embryos were protected 246 
from light except during illumination for 10 minutes with the LumiSource, at 34 hours post 247 
fertilization. They were separately maintained in E3 medium which was refreshed daily. 248 
Survival was monitored until 6 days post fertilization.  The blue light LumiSource lamp was 249 
used to illuminate zebrafish embryos for two reasons: 1) Since zebrafish embryos are 250 
transparent and thin, deep tissue penetration of light is therefore not needed and the blue light 251 
(λmax ≈ 420 nm) is capable of penetrating the embryos for in vivo light-activation of TPCS2a; 2) 252 
The LumiSource lamp is a practical way to simultaneously illuminate multiple zebrafish 253 
embryos since it has a light emission surface area of 765 cm2. 254 
 255 
Statistical analysis 256 
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For in vitro studies with RAW cells, data were analyzed by one-way ANOVA, and 257 
subsequently groups were compared pairwise by either Dunnett’s or Sidak’s multiple 258 
comparisons tests, depending on the experimental setup. Percent survival of embryos and 259 
differences between pairs of survival curves were analyzed using the Kaplan-Meier method and 260 
log rank test, respectively. Differences were considered significant for P values ≦ 0.05.  All 261 
analyses were performed using GraphPad Prism 7.0.  262 
263 
Results 264 
Effect of gentamicin, TPPS2a and TPPS2a-S. epidermidis combination on 265 
metabolic activity and viability of RAW cells  266 
Exposure to up to 250 µg/ml of gentamicin for 24 hours did not reduce the metabolic activity 267 
of RAW cells. Without illumination, 0.4 µg/ml of TPPS2a did not reduce the metabolic activity. 268 
With illumination for 15 minutes, concentrations of TPPS2a up to 0.25 µg/ml did not reduce the 269 
metabolic activity, neither immediately after illumination (T = 0) nor after 24 (T = 24) or 48 270 
hours (T = 48) (Figure 1a). Hence, we chose 250 µg/ml of gentamicin and 0.25 µg/ml of TPPS2a 271 
as the maximum concentrations for further experiments. 272 
The effect of TPPS2a-PCI treatment alone or in presence of S. epidermidis on viability of RAW 273 
cells was assessed immediately (T = 0) and at 1 hour after illumination for 0, 5, 10 or 15 minutes 274 
(T = 1) (Figure 1b). Cells illuminated in absence of TPPS2a served as controls. Illumination as 275 
such did not influence cell viability. Cells exposed to TPPS2a alone or combined with S. 276 
epidermidis showed significant reduction of viability when illuminated for 5-15 minutes and 277 
for 10-15 minutes, respectively (Figure 1b).  278 
 14
 279 
Figure 1. Effect of TPPS2a and TPPS2a combined with S. epidermidis on metabolic activity and 280 
viability of RAW cells. a) Metabolic activity of RAW cells expressed as percent conversion of 281 
WST-1 reagent relative to that of non-treated cells (0 µg/ml). Differences between the TPPS2a-282 
treated groups and the non-treated group were analyzed using Dunnett’s multiple comparisons 283 
test; b) Viability of RAW cells  recorded as percentage of cells not permeable to propidium 284 
iodide. The cells were treated with illumination only, with TPPS2a and illumination, or with 285 
TPPS2a combined with S. epidermidis and illumination. Differences between indicated groups 286 
were analyzed using Dunnett’s multiple comparisons test; Data represent mean ± standard 287 
deviation (n=3) in Panel a and b, *, P ≦ 0.05; **, P < 0.01; ***, P < 0.001.  288 
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PCI-induced cytosolic release of gentamicin enhances efficacy against 289 
intracellular S. epidermidis in RAW cells  290 
 291 
Figure 2. PCI-enhanced efficacy of gentamicin against intracellular S. epidermidis in RAW 292 
cells. a) Reduction of numbers of CFU of intracellular S. epidermidis by TPPS2a-PCI of 293 
gentamicin. Cells containing S. epidermidis were illuminated only, treated with 0.25 µg/ml 294 
TPPS2a or gentamicin (GEN) only or with GEN-TPPS2a combinations. Cells subsequently were 295 
illuminated for 0, 10 or 15 minutes. Differences between GEN alone and respective GEN-296 
TPPS2a treatments were analyzed using Sidak’s multiple comparisons test. Data represent mean 297 
 16
± standard deviation (n=3). *, P ≦ 0.05, ***, P < 0.001; b) PCI-induced cytosolic release of 298 
gentamicin in RAW cells upon illumination. Gentamicin was labeled with Alexa Fluor 405 299 
(blue) and TPCS2a was observed in the red channel. Intracellular co-localization of gentamicin 300 
and TPCS2a is shown as magenta color in the merged images. Scale bars = 10 µm. (in color) 301 
 302 
To study whether TPPS2a with illumination itself would kill bacteria, we exposed S. epidermidis 303 
bacteria to TPPS2a at concentrations of up to 0.5 g/ml and illuminated the bacteria. The 304 
numbers of CFU of S. epidermidis were not reduced after incubation with TPPS2a and 305 
illumination, showing that TPPS2a with illumination has no inhibitory or cidal effect on the 306 
bacteria.  307 
To investigate whether TPPS2a-PCI enhanced the efficacy of gentamicin against intracellular S. 308 
epidermidis in vitro, we exposed S. epidermidis-infected RAW cells to TPPS2a only (0.25 309 
µg/ml), to gentamicin only (1, 10 or 30 µg/ml) or to the respective gentamicin-TPPS2a 310 
combinations (Figure 2a). Since with 5 minutes of illumination no effect of the gentamicin-311 
TPPS2a combinations was observed (data not shown), cells were illuminated for 10 or 15 312 
minutes. Treated but non-illuminated cells and cells only illuminated served as controls. 313 
Without illumination, none of the treatments caused reduction of the numbers of intracellular 314 
bacteria in RAW cells. Treatment with TPPS2a-illumination or only with illumination did not 315 
affect intracellular survival of S. epidermidis. None of the treatments with gentamicin only, 316 
with or without illumination for 10 or 15 minutes, showed significant reduction in numbers of 317 
CFU of intracellular S. epidermidis. Treatment with TPPS2a and 30 µg/ml gentamicin with 318 
illumination for 10 minutes significantly enhanced killing of intracellular bacteria (1 log 319 
reduction). With illumination for 15 minutes, combination of TPPS2a and either 10 or 30 µg/ml 320 
gentamicin significantly increased killing of intracellular S. epidermidis to levels of 1 and 3 log 321 
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reduction, respectively. A repetition experiment showed highly similar results (Figure S3, 322 
Supplementary data).  323 
To investigate whether PCI induced cytosolic release of gentamicin, intracellular distribution 324 
of gentamicin and photosensitizer in RAW cells with and without illumination was visualized 325 
(Figure 2b). For these and subsequent in vivo studies with zebrafish embryos we selected 326 
TPCS2a. This photosensitizer absorbs red light which has a favorable tissue penetration, and 327 
therefore is more suitable for applications in vivo than TPPS2a [36]. Without illumination, both 328 
gentamicin and TPCS2a localized within intracellular compartments in the periphery of the cells, 329 
likely endocytic vesicles. After illumination both gentamicin and TPCS2a were released into the 330 
cytosol. Gentamicin seemed to accumulate at the nuclei of the RAW cells.  331 
 332 
Dose finding of S. aureus for zebrafish embryo infection and visualization of 333 
cell-pathogen interaction in vivo 334 
To assess suitable doses of S. aureus for zebrafish embryo infection, we injected graded inocula 335 
with doses of 6000, 3000, 500 or 100 CFU per embryos into the blood circulation at 30 hours 336 
post fertilization. The actual doses of bacteria injected were close to the aimed doses with minor 337 
variations in each group (Figure 3a). Death rate of S. aureus-infected embryos was proportional 338 
to the inoculum dose (Figure 3b). The dose of 3000 CFU/embryo caused approximately 50% 339 
of the embryos to die at 4 days post injection (Figure 3b), which is suitable to assess the efficacy 340 
of antibiotic treatment.  341 
In order to investigate whether S. aureus was phagocytosed shortly after injection, we 342 
challenged 1 day old transgenic zebrafish embryos expressing Kaede green fluorescent protein 343 
in their macrophages (Figure 4d), with 3000 CFU of mCherry red fluorescent protein-344 
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expressing S. aureus. We chose the time point of 2 hours post injection to assess whether the 345 
injected S. aureus were phagocytosed by zebrafish macrophages since the majority of S. aureus 346 
are taken up by zebrafish macrophages and/or neutrophils with 2 hours post injection, and these 347 
cells containing bacteria are important niches for S. aureus infection in the embryos [4, 37]. In 348 
the present study co-localization of S. aureus and macrophages was observed in the blood 349 
circulation at 2 hours post injection (Figure 3d). The bacteria not associated with labelled 350 
phagocytes seemed to be clustered (Figure 3d), suggesting that they were phagocytosed by the 351 
non-labelled phagocyte type of the embryos such as neutrophils. This shows that (a portion of) 352 
S. aureus had been phagocytosed in vivo at 2 hours post injection, which is in line with the 353 
results reported in the previous studies [4, 37].  354 
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 355 
Figure 3. Determination of S. aureus challenge doses for zebrafish embryo infection and co-356 
localization of S. aureus and zebrafish macrophages. a) CFU numbers of S. aureus cultured 357 
from crushed embryos injected with inocula of 100 to 6000 CFU in 1 nl PBS. The red lines 358 
represent the median numbers of CFU. b) Effect of different inocula of S. aureus on survival 359 
of embryos. PBS injections served as controls. Initial group sizes ranged from 26 to 38 embryos. 360 
c) Bright field image of a representative 1 day old zebrafish embryo at 2 hours post S. aureus 361 
injection. Scale bar = 500 µm. The blue box indicates the area shown in d) at high magnification 362 
with co-localization of S. aureus-mCherry (red) and zebrafish macrophages (green) as co-363 
localization in yellow (arrows). Scale bars = 100 µm in d). (in color) 364 
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 365 
Enhanced survival of S. aureus-infected embryos treated with gentamicin 366 
combined with PCI  367 
 368 
Figure 4. Survival of non-infected and S. aureus-infected zebrafish embryos treated with 369 
gentamicin only or gentamicin-TPCS2a combinations after illumination for 10 min. a) Effect of 370 
gentamicin alone (GEN) or combined with TPCS2a (T) (in 1 nl of PBS) on non-infected embryos. 371 
Embryos injected with PBS served as controls. Initial group sizes ranged from 31 to 35 embryos; 372 
b) Survival of embryos infected with 3000 CFU of S. aureus treated with gentamicin only or 373 
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combined with TPCS2a. PBS mock treatment served as control. Initial group size ranged from 374 
31 to 33 embryos. Differences between survival of each of the treated groups versus the PBS 375 
control group, as well as between survival of the gentamicin only group and the respective 376 
gentamicin-TPCS2a treatment group were analyzed using Log-rank test.  **, p < 0.01. ***, p < 377 
0.001. (in color) 378 
 379 
To test their toxicity for zebrafish embryos, the effect of injection of graded doses of gentamicin, 380 
TPCS2a and gentamicin-TPCS2a combinations on survival was assessed. TPCS2a and 381 
gentamicin both showed a dose-dependent toxicity, with maximal non-toxic concentrations of 382 
2.5 x 10-3 and 2 ng/embryo, respectively (Figure S4 a and b, Supplementary data). 383 
Combinations of 1.6 or 0.8 ng/embryo gentamicin with 2.5 x 10-3 ng/embryo TPCS2a did not 384 
significantly reduce survival of embryos (Figure 4a).  385 
To investigate whether PCI enhanced the efficacy of gentamicin against staphylococcal 386 
infection in vivo, we treated S. aureus-infected zebrafish embryos (3000 CFU/embryo) with 387 
gentamicin alone or combined with TPCS2a (Figure 4b). All treatments significantly improved 388 
survival as compared to the PBS mock treatment. Addition of TPCS2a significantly improved 389 
the treatment efficacy of 0.1 ng gentamicin, resulting in levels of survival similar to those 390 
obtained with treatment of 0.4 ng gentamicin alone. This shows that PCI enhances the efficacy 391 
of gentamicin against S. aureus infection in vivo in zebrafish embryos and lowers the required 392 
dose for efficacy. However, a minimal gentamicin dosing is necessary to observe the enhancing 393 
effect of TPCS2a, since TPCS2a did not improve the efficacy of 0.05 ng gentamicin. 394 
 395 
Discussion 396 
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Intracellular niches are considered a ”safe haven” for intracellular bacterial pathogens such as 397 
staphylococci, where they are protected from clearance by the host [1-3, 8, 10]. Intracellular 398 
infections are very difficult to treat with most conventional antibiotics, and even are considered 399 
part of the cause of antibiotic resistance development [2, 11, 16]. Although some approaches 400 
such as using micro-/nano-sized vehicles as carriers for delivery of antibiotics [11, 12, 14, 17] 401 
and conjugation of antibiotics to cell penetrating peptides or specific antibodies [18-20] are 402 
reported to improve their cell penetration,  endosomal entrapment of antibiotics after 403 
endocytosis still remains a major problem, resulting in low bioavailability of the drugs in the 404 
cytosol [22, 23]. Therefore, novel approaches to enhance intracellular activity of antibiotics are 405 
urgently needed. In our study, we have devised and applied a novel use of photochemical 406 
internalization (PCI) as a means of controlled release of antibiotics into the cytosol, targeting 407 
intracellular bacteria. We have applied PCI to enhance intracellular activity of gentamicin, an 408 
antibiotic with limited efficacy inside cells, against staphylococci both in vitro and in vivo. In 409 
RAW cells, PCI induced cytosolic release of gentamicin and increased eradication of 410 
phagocytosed S. epidermidis. In vivo, in a zebrafish embryo model with S. aureus internalized 411 
by phagocytes, PCI enhanced efficacy of gentamicin against S. aureus infection and lowered 412 
the required dose of the antibiotic. To the best of our knowledge, our study is the first to 413 
demonstrate the potential of PCI to enhance antimicrobial efficacy of an antibiotics inside cells 414 
and thus provides a new concept for treating intracellular infections. 415 
Photosensitizers such as TPPS2a and TCPS2a have been developed for treatment of tumors by 416 
enhancing delivery of cytotoxic chemotherapeutics [24, 25, 38]. According to the principle of 417 
PCI, the doses of photosensitizer and light required to disrupt the endosomal/lysosomal 418 
membranes are likely sublethal [39]. In our study, although PCI had slight to moderate levels 419 
of cytotoxicity for RAW cells in vitro (Figure 1b), the concentrations required to enhance the 420 
efficacy of gentamicin in vivo did not significantly reduce survival of the zebrafish embryos 421 
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(Figure S4). Similarly, in a recent clinical phase I trial for delivery of the antitumor drug 422 
bleomycin TPCS2a-PCI was shown to be safe and tolerable for human patients receiving 423 
infusions of TPCS2a solution [38].TPPS2a and TPCS2a molecules tend to preferentially 424 
accumulate in diseased tissues and inflamed areas [24, 25], and other similar types of 425 
photosensitizers were shown to be internalized by local highly active cells in inflamed areas, 426 
such as macrophages and neutrophils [40, 41]. Therefore, treatment of infected areas by PCI 427 
combined with antibiotic therapy will likely preferentially target phagocytic cells containing 428 
bacteria. Moreover, any cytotoxicity of photosensitizers will only be induced when illumination 429 
is applied. Therefore, application of site-specific illumination to diseased tissues/inflamed areas 430 
will minimize the potential side effects of PCI on healthy tissues and normal cells which are 431 
not exposed to illumination. Compared to chemical endosomal disruption agents such as 432 
chloroquine, ammonium chloride and methylamine which have relatively high toxicity and low 433 
cell/tissue specificity [42, 43],  PCI provides temporally and spatially controlled cytosolic 434 
release of therapeutics from endocytic vesicles with potentially less side effects in vivo [24, 44].  435 
Treatment of S. epidermidis-infected RAW cells by gentamicin alone, even with relatively high 436 
concentrations (10 and 30 µg/ml), did not remarkably reduce the numbers of the intracellular 437 
bacteria. Combining the treatment with PCI however significantly improved the efficacy 438 
(Figure 2). A similar efficacy-enhancing effect of PCI was observed in vivo in our zebrafish 439 
embryo S. aureus infection model (Figure 4). PCI did however not increase the efficacy of the 440 
lowest dose of gentamicin, neither in vitro nor in vivo. Possibly the amount of intracellular 441 
gentamicin was too low to be efficacious even after cytosolic release following PCI treatment. 442 
Interestingly, in our experiments with RAW cells the liberated gentamicin molecules seemed 443 
to accumulate at the nuclei after illumination. This is in line with the observation of gentamicin 444 
binding to the nuclei of kidney cells [45]. Although theoretically such binding may reduce the 445 
amount of free gentamicin in the cytosol, enhanced efficacy of gentamicin by PCI (4-fold) was 446 
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still observed in our study. This suggests that intracellular activity of antibiotics which do not 447 
show nuclear binding, might be even more strongly enhanced by PCI. Our results, showing an 448 
enhancing effect of PCI on antibiotic efficacy in the zebrafish embryo infection model, offer 449 
prospects for further in vivo studies in larger mammalian animal models. In vivo studies with 450 
PCI in mouse models have already been performed extensively for cancer treatment[46, 47]. 451 
The available relevant information on PCI modality from these studies supports further 452 
investigation on PCI-antibiotic treatment of intracellular infection in vivo. Moreover, since the 453 
photosensitizer TPCS2a has passed clinical phase I trials for safety testing in human patients [38] 454 
and many antibiotics to be combined with PCI are available, there is the possibility to relatively 455 
rapidly progress towards clinical studies of PCI-antibiotic treatment of diseases associated with 456 
intracellular infections.  457 
Eradication of intracellular bacteria by antibiotics may be impeded by their different subcellular 458 
localization inside cells [13, 27]. Even when endosomes containing antibiotics and 459 
photosensitizers would be ruptured after illumination, bacteria might still be safely shielded 460 
within phagosomes, which would not necessarily contain photosensitizers. Our results however 461 
did show increase of killing of the intracellular bacteria. This may be explained in two ways. 462 
After rupture of the endosomes containing antibiotics, photosensitizer molecules dissociated 463 
from the lysed endosomal membranes may intracytoplasmically re-localize to the membranes 464 
of phagosomes containing the bacteria, and also rupture these membranes (Scheme 1). As a 465 
result, bacteria are released into the cytosol and are intracellularly killed by gentamicin. In 466 
addition, during PCI partially ruptured vesicles are suggested to fuse with still intact 467 
intracellular vesicles causing them to also become leaky/ruptured, even without additional 468 
illumination [29]. Such fusion therefore may also (partially) contribute to the cytosolic release 469 
of both antibiotics and bacteria, facilitating the intracellular antimicrobial action. Since 470 
intracellular delivery of bioactive molecules using PCI generally does not rely on particular 471 
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properties of the molecules to be delivered [24, 25], PCI can likely also improve the intracellular 472 
efficacy of other antibiotics than gentamicin via controlled release of drugs into the cytosol of 473 
cells. Such antibiotics may be other aminoglycosides, glycopeptides and macrolides, whose 474 
activity likely is limited by their inability of endosomal escape [13, 26, 27]. PCI thus has a 475 
strong potential to increase the numbers of antibiotics to be effective in treatment of 476 
intracellular infection and may increase their therapeutic window, since PCI will lower the 477 
effective antibiotic dose owing to enhanced intracellular delivery. Because PCI can in principle 478 
enhance intracellular delivery of different antibiotics, it has the potential to enhance efficacy of 479 
antibiotic treatment of infections caused by a broad range of intracellular bacterial pathogens 480 
such as Mycobacterium tuberculosis, Listeria monocytogenes and Salmonella typhi [11, 12]. 481 
As a result, PCI may also help reduce the rate of resistance development which might occur 482 
intracellularly due to the low, permissive concentration of antibiotics.  483 
Infectious diseases involving intracellular bacteria can occur or relapse at different sites of the 484 
human body (e.g. skin, deep tissues, urinary tract and lung). In addition to professional 485 
phagocytes, non-professional phagocytic cells (e.g. epithelial cells, osteoblasts) can be niches 486 
for intracellular bacteria [1, 2, 11]. The potential of PCI-antibiotic combinations to treat such 487 
local infections is dependent on whether light can be applied to the site of infection with 488 
intracellular bacteria. Similar to antibacterial photodynamic therapy (aPDT) [48-50], PCI can 489 
be considered for local treatment of (sub)cutaneous skin or mucosal infections such as infected 490 
chronic wounds, ulcers, abscesses and diabetic foot infection as well as for nasal and oral 491 
infections (e.g. chronic rhinosinusitis and periodontal infections), where the site of infection is 492 
accessible for light required for the controlled release of antibiotics. The PCI-antibiotic 493 
treatment of infections of internal organs, deep tissue or bone is more challenging, but certainly 494 
not impossible. Techniques such as those developed for clinical applications of PDT in the 495 
treatment of tumors in bile duct, lung, brain and bladder [51] offer a good toolset to develop 496 
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PCI-enhanced treatment for deep infections. Consequently, PCI has strong potential to improve 497 
antibiotic treatment of intracellular infections in a broad spectrum of clinically challenging 498 
infectious diseases.  499 
 500 
Conclusions  501 
In our in vitro mouse macrophage as well as in vivo zebrafish embryo studies, we demonstrate 502 
that photochemical internalization (PCI) can significantly enhance the antimicrobial efficacy of 503 
an antibiotic with limited activity (e.g. gentamicin) against (intracellular) staphylococcal 504 
infection, likely owing to the cytosolic release of the antibiotic. To the best of our knowledge 505 
we are the first to report an entirely novel application of PCI, i.e. to specifically enhance the 506 
efficacy of antibiotics against intracellular infections. This opens new avenues to improve the 507 
antibiotic treatment of infections associated with intracellular survival of bacteria and may also 508 
help prevent resistance development.    509 
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